

Claudia R Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/487702/publications.pdf>

Version: 2024-02-01

121
papers

5,000
citations

126708

33
h-index

91712

69
g-index

124
all docs

124
docs citations

124
times ranked

3935
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 81.	3.8	619
2	Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. <i>Blood</i> , 2006, 107, 2279-2285.	0.6	561
3	Arginine Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 63-69.	2.5	302
4	Decreased Arginine Bioavailability and Increased Serum Arginase Activity in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 148-153.	2.5	252
5	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. <i>Blood</i> , 2011, 118, 855-864.	0.6	210
6	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 727-740.	2.5	197
7	Patterns of Arginine and Nitric Oxide in Patients With Sickle Cell Disease With Vaso-occlusive Crisis and Acute Chest Syndrome. <i>The American Journal of Pediatric Hematology/oncology</i> , 2000, 22, 515-520.	1.3	176
8	Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. <i>Blood</i> , 2008, 111, 402-410.	0.6	157
9	Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 177-185.	0.9	146
10	A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. <i>Haematologica</i> , 2013, 98, 1375-1382.	1.7	130
11	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. <i>Circulation</i> , 2011, 124, 1452-1460.	1.6	124
12	Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine. <i>Nutrition in Clinical Practice</i> , 2017, 32, 30S-47S.	1.1	110
13	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. <i>PLoS ONE</i> , 2014, 9, e99489.	1.1	107
14	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. <i>SHORT REPORT. British Journal of Haematology</i> , 2000, 111, 498-500.	1.2	102
15	Hemolysis-Associated Pulmonary Hypertension in Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 481-485.	1.8	96
16	Nitric Oxide and Arginine Dysregulation: A Novel Pathway to Pulmonary Hypertension in Hemolytic Disorders. <i>Current Molecular Medicine</i> , 2008, 8, 620-632.	0.6	95
17	Asthma management: Reinventing the wheel in sickle cell disease. <i>American Journal of Hematology</i> , 2009, 84, 234-241.	2.0	91
18	Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 629-634.	0.3	79

#	ARTICLE	IF	CITATIONS
19	Summary Points and Consensus Recommendations From the International Protein Summit. <i>Nutrition in Clinical Practice</i> , 2017, 32, 142S-151S.	1.1	75
20	Altered amino acid profile in patients with SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	68
21	Pulmonary hypertension in thalassemia. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 205-213.	1.8	61
22	Vascular risk assessment in patients with sickle cell disease. <i>Haematologica</i> , 2011, 96, 1-5.	1.7	60
23	Pulmonary hypertension and NO in sickle cell. <i>Blood</i> , 2010, 116, 852-854.	0.6	59
24	Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. <i>European Journal of Haematology</i> , 2009, 82, 315-321.	1.1	58
25	L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. <i>British Journal of Haematology</i> , 2003, 120, 532-534.	1.2	55
26	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. <i>Blood</i> , 2011, 118, 3794-3802.	0.6	55
27	Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. <i>British Journal of Haematology</i> , 2008, 140, 104-112.	1.2	50
28	Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 695972.	2.2	50
29	Alterations of the Arginine Metabolome in Sickle Cell Disease. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 301-321.	0.9	45
30	New Strategies for the Treatment of Pulmonary Hypertension in Sickle Cell Disease. <i>Treatments in Respiratory Medicine</i> , 2006, 5, 31-45.	1.4	42
31	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. <i>Haematologica</i> , 2013, 98, 1359-1367.	1.7	40
32	Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. <i>British Journal of Haematology</i> , 2000, 111, 498-500.	1.2	38
33	Arginase and Arginine Dysregulation in Asthma. <i>Journal of Allergy</i> , 2011, 2011, 1-12.	0.7	37
34	Outcomes of SARS-CoV-2â€“Positive Youths Tested in Emergency Departments. <i>JAMA Network Open</i> , 2022, 5, e2142322.	2.8	35
35	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2019, 16, e17-e32.	1.5	33
36	The role of the arginine metabolome in pain: implications for sickle cell disease. <i>Journal of Pain Research</i> , 2016, 9, 167.	0.8	29

#	ARTICLE	IF	CITATIONS
37	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. PLoS ONE, 2014, 9, e101626.	1.1	28
38	Protein Requirements of the Critically Ill Pediatric Patient. Nutrition in Clinical Practice, 2017, 32, 128S-141S.	1.1	26
39	Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood, 2020, 136, 1402-1406.	0.6	26
40	Asthma in Sickle Cell Disease. Scientific World Journal, The, 2011, 11, 1138-1152.	0.8	24
41	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	3.8	24
42	Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. American Journal of Hematology, 2021, 96, 89-97.	2.0	23
43	Clinical hemoglobinopathies: iron, lungs and new blood. Current Opinion in Internal Medicine, 2007, 6, 60-71.	1.5	22
44	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	1.2	22
45	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21
46	Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). Experimental Biology and Medicine, 2021, 246, 2543-2552.	1.1	20
47	Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain. American Journal of Hematology, 2019, 94, 689-696.	2.0	17
48	Latent Class Analysis of School-Age Children at Risk for Asthma Exacerbation. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2275-2284.e2.	2.0	16
49	Acceptability and Barriers to HIV Pre-Exposure Prophylaxis in Atlanta's Adolescents and Their Parents. AIDS Patient Care and STDs, 2019, 33, 425-433.	1.1	14
50	Asymptomatic Adolescent HIV: Identifying a Role for Universal HIV Screening in the Pediatric Emergency Department. AIDS Patient Care and STDs, 2020, 34, 373-379.	1.1	13
51	Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.. Blood, 2009, 114, 571-571.	0.6	13
52	Arginine and Asthma. Nestle Nutrition Institute Workshop Series, 2013, 77, 1-15.	1.5	12
53	Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vaso-occlusive pain episodes in a pediatric emergency department. American Journal of Hematology, 2018, 93, E205.	2.0	12
54	Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: A single institution experience. Pediatric Blood and Cancer, 2018, 65, e26742.	0.8	11

#	ARTICLE	IF	CITATIONS
55	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. <i>Blood</i> , 2011, 118, 2125-2125.	0.6	11
56	What is the future of patient-reported outcomes in sickle-cell disease?. <i>Expert Review of Hematology</i> , 2020, 13, 1165-1173.	1.0	10
57	Pulmonary Hypertension in Thalassemia: Association with Hemolysis, Arginine Metabolism Dysregulation, and a Hypercoagulable State. <i>Advances in Pulmonary Hypertension</i> , 2007, 6, 31-38.	0.1	10
58	Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention. <i>Expert Review of Hematology</i> , 2017, 10, 875-890.	1.0	9
59	The Relationship Between Parents' Reported Storage of Firearms and Their Children's Perceived Access to Firearms: A Safety Disconnect. <i>Clinical Pediatrics</i> , 2021, 60, 42-49.	0.4	9
60	Syndrome of allergy, apraxia, and malabsorption: characterization of a neurodevelopmental phenotype that responds to omega 3 and vitamin E supplementation. <i>Alternative Therapies in Health and Medicine</i> , 2009, 15, 34-43.	0.0	8
61	Arginine Therapy and Cardiopulmonary Hemodynamics in Hospitalized Children with Sickle Cell Anemia: A Prospective, Double-blinded, Randomized Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 70-80.	2.5	8
62	Characteristics of Children and Adolescents Diagnosed With HIV By Targeted and Diagnostic Testing in a Children's Hospital Network. <i>Academic Emergency Medicine</i> , 2018, 25, 1306-1309.	0.8	7
63	Comparison of cost and resource utilization between firearm injuries and motor vehicle collisions at pediatric hospitals. <i>Academic Emergency Medicine</i> , 2021, 28, 630-638.	0.8	7
64	Oral Arginine Increases Erythrocyte Glutathione Levels in Sickle Cell Disease: Implications for Pulmonary Hypertension.. <i>Blood</i> , 2006, 108, 1208-1208.	0.6	7
65	A Quality Improvement Initiative to Improve Emergency Department Care for Pediatric Patients with Sickle Cell Disease. <i>Journal of Clinical Outcomes Management</i> , 2014, 21, 62-70.	1.7	7
66	Assessment of Protein Turnover in Health and Disease. <i>Nutrition in Clinical Practice</i> , 2017, 32, 15S-20S.	1.1	6
67	Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers. <i>International Journal of Infectious Diseases</i> , 2021, 105, 474-481.	1.5	6
68	The Arginine-to-Ornithine Ratio: Biomarker of Arginase Activity and Predictor of Mortality in Sickle Cell Disease.. <i>Blood</i> , 2004, 104, 237-237.	0.6	6
69	Role of Arginase in Sickle Cell Lung Disease and Hemolytic Anemias-!2009-11-12-!2010-03-16-!2010-05-04-!. <i>The Open Nitric Oxide Journal</i> , 2010, 2, 41-54.	0.4	6
70	Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	6
71	Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway. <i>Current Hypertension Reviews</i> , 2007, 3, 223-230.	0.5	5
72	Arginine Therapy for Vaso-Occlusive Pain Episodes in Sickle Cell Disease.. <i>Blood</i> , 2009, 114, 573-573.	0.6	5

#	ARTICLE	IF	CITATIONS
73	Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: Preliminary Pharmacokinetics Results. <i>Blood</i> , 2010, 116, 1636-1636.	0.6	5
74	Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study. <i>Complementary Therapies in Medicine</i> , 2022, 64, 102803.	1.3	5
75	Are we missing the mark? Fever, respiratory symptoms, chest radiographs, and acute chest syndrome in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, E332-3.	2.0	4
76	Arginine Therapy Shows Promise for Treatment of Sickle Cell Disease Clinical Subphenotypes of Hemolysis and Arginine Deficiency. <i>Anesthesia and Analgesia</i> , 2017, 124, 1369-1370.	1.1	4
77	Do Our Adolescents Know They Are Cyberbullying Victims?. <i>Journal of Infant, Child, and Adolescent Psychotherapy</i> , 2019, 18, 93-101.	0.4	4
78	Utility of Point-of-Care Lung Ultrasonography for Evaluating Acute Chest Syndrome in Young Patients With Sickle Cell Disease. <i>Annals of Emergency Medicine</i> , 2020, 76, S46-S55.	0.3	4
79	Pediatric firearm and motor vehicle collision injuries in the United States: Diverging trends. <i>American Journal of Emergency Medicine</i> , 2022, 53, 59-62.	0.7	4
80	Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation?. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 308-311.e9.	1.5	3
81	Validation of a composite vascular high-risk profile for adult patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E312-E314.	2.0	3
82	Unique Needs for the Implementation of Emergency Department Human Immunodeficiency Virus Screening in Adolescents. <i>Academic Emergency Medicine</i> , 2020, 27, 984-994.	0.8	3
83	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. <i>Blood</i> , 2009, 114, 2016-2016.	0.6	3
84	Quality Improvement Goals for Sickle Cell Disease Pain Management in an Urban Pediatric Emergency Department: We Can Do Better!.. <i>Blood</i> , 2012, 120, 2101-2101.	0.6	3
85	The effects of glutamine supplementation on markers of apoptosis and autophagy in sickle cell disease peripheral blood mononuclear cells. <i>Complementary Therapies in Medicine</i> , 2022, 70, 102856.	1.3	3
86	Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide. <i>Academic Emergency Medicine</i> , 2019, 26, 1102-1105.	0.8	2
87	The need for new test verification and regulatory support for innovative diagnostics. <i>Nature Biotechnology</i> , 2021, 39, 1060-1062.	9.4	2
88	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. <i>Blood</i> , 2012, 120, 1023-1023.	0.6	2
89	Response to "Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up " <i>Haematologica</i> 2014;99(2):e17-18.. <i>Haematologica</i> , 2014, 99, e19-e19.	1.7	1
90	Acceptability and Barriers to Pre-exposure Prophylaxis (PrEP) in Atlanta's Adolescents and Their Parents. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1

#	ARTICLE	IF	CITATIONS
91	Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress. <i>Blood</i> , 2019, 134, 995-995.	0.6	1
92	Pulmonary Hypertension in Sickle Cell Disease: A Common Complication for Both Adults and Children.. <i>Blood</i> , 2004, 104, 1666-1666.	0.6	1
93	Abnormal Pulmonary Function in Adults and Children with Sickle Cell Disease.. <i>Blood</i> , 2005, 106, 2319-2319.	0.6	1
94	Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. <i>Blood</i> , 2012, 120, 3240-3240.	0.6	1
95	Elevated Plasma Arginase Levels in Hemoglobinopathies.. <i>Blood</i> , 2005, 106, 2346-2346.	0.6	1
96	Erythrocyte Glutathione Depletion Is Associated with Severity of Anemia and Pulmonary Hypertension in Patients with Sickle Cell Disease.. <i>Blood</i> , 2006, 108, 788-788.	0.6	1
97	Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. <i>Blood</i> , 2010, 116, 947-947.	0.6	1
98	Non-Cardiopulmonary Factors Affecting the Six-Minute Walk Distance in Patients with Sickle Cell Disease: Results From the Walk-PHaSST Study. <i>Blood</i> , 2011, 118, 1074-1074.	0.6	1
99	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. <i>Blood</i> , 2012, 120, 2122-2122.	0.6	1
100	Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies. <i>Blood</i> , 2020, 136, 7-8.	0.6	1
101	Impact of Oral Arginine Therapy on Global Arginine Bioavailability in Nigerian Children with Sickle Cell Anemia and Vaso-Occlusive Pain. <i>Blood</i> , 2020, 136, 22-23.	0.6	1
102	Predictive Value of Isolated Symptoms for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children Tested During Peak Circulation of the Delta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 1131-1139.	2.9	1
103	The Development and Acceptability of a Comprehensive Crisis Prevention Program for Implementation in Health Care Settings. <i>Journal of the American Psychiatric Nurses Association</i> , 2022, , 107839032210935.	0.4	1
104	l-Arginine Therapy in Sickle Cell Disease. , 2017, , 497-512.		0
105	The Defective Arginine-Nitric Oxide Pathway in Sickle Cell Disease. , 2017, , 355-371.		0
106	Upward Trends of Parotitis and Mumps in Atlanta over a Decade. <i>Global Pediatric Health</i> , 2020, 7, 2333794X2096867.	0.3	0
107	A multicenter evaluation of viral bloodstream detections in children presenting to the Emergency Department with suspected systemic infection. <i>BMC Pediatrics</i> , 2021, 21, 238.	0.7	0
108	Reply to Letter to the Editor regarding hospital-based triage travel screens during the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 107, 165.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Pulmonary Hypertension: A Common Complication in Thalassemia.. Blood, 2004, 104, 3612-3612.	0.6	0
110	Dysregulated Arginine Metabolism and Elevated Arginase Activity in Thalassemia.. Blood, 2005, 106, 3644-3644.	0.6	0
111	Low Erythrocyte Glutamine-to-Glutamate Ratio: A Novel Biomarker of Hemolysis and Pulmonary Hypertension in Sickle Cell Disease.. Blood, 2007, 110, 2257-2257.	0.6	0
112	High Frequency of Asthma, Sepsis and Acute Chest Syndrome in Children with Sickle Cell Disease and Pulmonary Hypertension.. Blood, 2007, 110, 3782-3782.	0.6	0
113	NT-Probnp as a Marker of Cardiopulmonary Compromise and Exercise Limitation In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood, 2010, 116, 1639-1639.	0.6	0
114	Chronic Pain Is An Independent Predictor of Lower 6 Minute Walk Distance In Patients with Sickle Cell Disease: Results From Walk-PHaSST Study. Blood, 2010, 116, 2658-2658.	0.6	0
115	Cigarette Smoking Is An Independent Predictor of Chronic Pain In Sickle Cell Patients: Results From the Walk-PHaSST Study. Blood, 2010, 116, 4804-4804.	0.6	0
116	Tricuspid Regurgitant Jet Velocity (TRV), Biomarkers of Hemolysis, and Impact of Oxygen Therapy in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE). Blood, 2012, 120, 4752-4752.	0.6	0
117	Citrate Synthase Activity Is Increased In Children With Sickle Cell Disease (SCD) On Hydroxyurea (HU) Therapy. Blood, 2013, 122, 4690-4690.	0.6	0
118	More Rapid Delivery of Parenteral Analgesia By Adding Intranasal Fentanyl to the Management of Sickle Cell Disease Vaso-Occlusive Pain Episodes at a Pediatric Emergency Department. Blood, 2014, 124, 4083-4083.	0.6	0
119	Poor Sensitivity of Physician Assessment to Predict Acute Chest Syndrome in Children with Sickle Cell Disease and Fever. Blood, 2015, 126, 2185-2185.	0.6	0
120	Are Subpleural Consolidations on Lung Ultrasound Early Findings of Acute Chest Syndrome?. Blood, 2016, 128, 4869-4869.	0.6	0
121	Targeted Proteomics of Pulmonary Hypertension in Sickle Cell Disease. Blood, 2021, 138, 981-981.	0.6	0